יחס חוב לטווח ארוך להון OncoCyte Inc (OCX)

OncoCyte Corporation aims to expand its B2B partner network through the implementation of the DetermaRx system, although current low order volumes hinder the reduction of average equipment costs. Price action on GURU.Markets serves as an indicator of this process, where the metric stands at 0.20. The business relies on the development of precise oncology tests, which, due to their exclusivity, allow the company to exercise pricing power and set premium rates for medical centers.

The commercial success of OncoCyte Corporation (OCX) depends on the integration of diagnostic tests into insurance programs, which requires stable funding. This process directly impacts the liability structure, as reflected in the ratio of long-term liabilities to equity. This metric measures the proportion of loans with a maturity of more than one year, determining the degree of financial stability. A decrease in this ratio indicates a healthier balance sheet and the minimization of risks. By analyzing financial leverage via long-term debt, an investor assesses the issuer's solvency.